Target intelligence / Profile preview

Histidine triad nucleotide-binding protein 3 (HINT3)

Target
HINT3
Molecular classification
Enzyme, Hydrolase, HIT (histidine triad) superfamily
01

Overview

Histidine triad nucleotide-binding protein 3 is an enzyme in the HIT (histidine triad) superfamily, characterized by the conserved His-ϕ-His-ϕ-His-ϕ-ϕ motif (ϕ = hydrophobic amino acid) near the C-terminus[1][4][6]. HINT3 functions as a nucleotide hydrolase and transferase, acting on the α-phosphate of ribonucleotides and showing preference for acyl-adenylate over nucleoside phosphoramidate substrates[1][4]. The enzyme exists mainly as a monomer and features unique structural elements compared to related family members such as HINT1 and HINT2[1]. Its endogenous substrates and precise physiological roles are still being elucidated, but it is thought to be involved in nucleotide metabolism and cellular response pathways, particularly in the context of cancer cell biology where its expression is regulated by retinoids[4][1][6]. HINT3 has not been implicated as a direct therapeutic target to date, and no inhibitors or drugs are documented to act on this molecule.

Other names
Adenosine 5'-monophosphoramidase HINT3HINT-3FLJ33126HINT4 (note: not synonymous with the distinct HINT4 gene/protein, but sometimes used in older sources)HIT-like protein
02

Mechanism of action

Not applicable (no known drugs), but its enzymatic mechanism involves hydrolysis of adenylate intermediates and nucleoside phosphoramidates via a key active-site histidine[4][1].

03

Biological functions

Nucleotide hydrolase (hydrolyzes acyl-AMP and nucleoside phosphoramidate substrates)[4][1][5]Transferase activity[4][1]Participates in hydrolysis of adenylate intermediates (e.g., aminoacyl-adenylates generated by lysyl-tRNA synthetase)[4]Involved in cellular response mechanisms, including potential effects on cell adhesion and survival in stress conditions in cancer biology[4]
04

Disease associations

Cancer (notably upregulated in hepatocellular carcinoma cells in response to all-trans retinoic acid treatment)[4]
05

Safety considerations

None specifically reported; no clinical targeting known, so no therapeutic safety data is available.
06

Interacting drugs

No specific drugs known to target HINT3 directly as of current data; no pharmacological modulators or tool compounds documented in the literature[4][5][1].
07

Biomarkers

HINT3 gene expression is increased in hepatocellular carcinoma cells upon all-trans retinoic acid treatment, suggesting biomarker potential for retinoid response or related cellular processes[4].

Beyond the preview

Go deeper on Histidine triad nucleotide-binding protein 3 (HINT3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histidine triad nucleotide-binding protein 3 (HINT3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call